Pigment Cell & Melanoma Research最新文献

{"title":"Overview of current melanoma therapies","authors":"Anna Fateeva,&nbsp;Kevinn Eddy,&nbsp;Suzie Chen","doi":"10.1111/pcmr.13154","DOIUrl":"10.1111/pcmr.13154","url":null,"abstract":"<p>Melanoma is the most aggressive type of skin cancer and is responsible for the majority of deaths from skin cancer. Therapeutic advances in the last few decades, notably the development of novel targeted therapies and immunotherapies have significantly improved patient outcomes; nonetheless, these options remain limited due to the onset of resistance to treatment modalities and relapse. In this review, we focus on the available therapeutic options, their benefits, and limitations.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 5","pages":"562-568"},"PeriodicalIF":3.9,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.13154","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138563761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myron Gordon Award Lecture 2023: Painting the neural crest: How studying pigment cells illuminates neural crest cell biology","authors":"Robert N. Kelsh","doi":"10.1111/pcmr.13147","DOIUrl":"10.1111/pcmr.13147","url":null,"abstract":"<p>It has been 30 (!!) years since I began working on zebrafish pigment cells, as a postdoc in the laboratory of Prof. Christiane Nüsslein-Volhard. There, I participated in the first large-scale mutagenesis screen in zebrafish, focusing on pigment cell mutant phenotypes. The isolation of <i>colourless</i>, <i>shady</i>, <i>parade</i> and <i>choker</i> mutants allowed us (as a postdoc in Prof. Judith Eisen's laboratory, and then in my own laboratory at the University of Bath since 1997) to pursue my ambition to address long-standing problems in the neural crest field. Thus, we have studied how neural crest cells choose individual fates, resulting in our recent proposal of a new, and potentially unifying, model which we call Cyclical Fate Restriction, as well as addressing how pigment cell patterns are generated. A key feature of our work in the last 10 years has been the use of mathematical modelling approaches to clarify our biological models and to refine our interpretations. None of this would have been possible without a hugely talented group of laboratory members and other collaborators from around the world—it has been, and I am sure will continue to be, a pleasure and privilege to work with you all!</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 5","pages":"555-561"},"PeriodicalIF":3.9,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.13147","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138443318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for sentinel lymph node metastasis in Korean acral and non-acral melanoma patients","authors":"Jee Yong Song,&nbsp;Young Jae Ryu,&nbsp;Ho Kyun Lee,&nbsp;Dong Hoon Lee,&nbsp;Yoo Duk Choi,&nbsp;Hyun Jeong Shim,&nbsp;Sook Jung Yun","doi":"10.1111/pcmr.13153","DOIUrl":"10.1111/pcmr.13153","url":null,"abstract":"<p>Breslow thickness, ulceration, and mitotic rate are well-known prognostic factors for sentinel lymph node (SLN) metastasis in cutaneous melanoma. We investigated risk factors, including especially the degree of pigmentation, for SLN metastasis in Korean melanoma patients. We enrolled 158, composed of Korean 107 acral and 51 non-acral melanoma patients who underwent SLN biopsy. Clinicopathologic features such as Breslow thickness, ulceration, mitotic rate, and the degree of pigmentation were evaluated. The recurrence-free survival (RFS) rate and date of recurrence were determined. Fifty-four patients (34.2%) had a positive SLN biopsy result. In a multivariate analysis, Breslow thickness (odds ratio [OR] 1.93; 95% confidence interval [CI], 1.12–3.47; <i>p</i> = .022) and heavy pigmentation (OR 13.14; 95% CI, 2.96–95.20, <i>p</i> = .002) were associated with SLN metastasis. Positive SLN patients had a higher rate of loco-regional and/or distant recurrence (hazard ratio 6.32; 95% CI, 3.39–11.79; <i>p</i> &lt; .001). Heavy pigmentation was associated with poor RFS. Heavy pigmentation is an independent predictor of SLN metastasis in both acral and non-acral melanoma. Our results suggest the need for in-depth SLN evaluation of cutaneous melanoma patients with heavy pigmentation and provide clinicians with important information for determining patient prognosis.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 3","pages":"332-342"},"PeriodicalIF":4.3,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138443319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MitoCur-1 induces ferroptosis to reverse vemurafenib resistance in melanoma through inhibition of USP14","authors":"Gege Li,&nbsp;Changlong Zhou,&nbsp;Lu Wang,&nbsp;Yalong Zheng,&nbsp;Bo Zhou,&nbsp;Guoyan Li,&nbsp;Zhongyu Ma,&nbsp;Peng Sun,&nbsp;Yuantao Deng,&nbsp;Li Su,&nbsp;Junling Wang,&nbsp;Hongmei Cui","doi":"10.1111/pcmr.13150","DOIUrl":"10.1111/pcmr.13150","url":null,"abstract":"<p>Melanoma is an aggressive malignant tumor with a poor prognosis. Vemurafenib (PLX4032, vem) is applied to specifically treat BRAF V600E-mutated melanoma patients. However, prolonged usage of vem makes patients resistant to the drug and finally leads to clinical failure. We previously tested the combination regimen of tubulin inhibitor VERU-111 with vem, as well as USP14 selective inhibitor b-AP15 in combination with vem, both of which have showed profound therapeutic effects in overcoming vem resistance in vitro and in vivo. Most importantly, we discovered that vem-resistant melanoma cell lines highly expressed E3 ligase SKP2 and DUB enzyme USP14, and we have demonstrated that USP14 directly interacts and stabilizes SKP2, which contributes to vem resistance. These works give us a clue that USP14 might be a promising target to overcome vem resistance in melanoma. MitoCur-1 is a curcumin derivative, which was originally designed to specifically target tumor mitochondria inducing redox imbalance, thereby promoting tumor cell death. In this study, we have demonstrated that it can work as a novel USP14 inhibitor, and thus bears great potential in providing an anti-tumor effect and sensitizing vem-resistant cells by inducing ferroptosis in melanoma. Application of MitoCur-1 dramatically induces USP14 inhibition and inactivation of GPX4 enzyme, meanwhile, increases the depletion of GSH and decreases SLC7A11 expression level. As a result, ferrous iron-dependent lipid ROS accumulated in the cell, inducing ferroptosis, thus sensitizes the vem-resistant melanoma cell. Interestingly, overexpression of USP14 antagonized all the ferroptosis cascade events induced by MitoCur-1, therefore, we conclude that MitoCur-1 induces ferroptosis through inhibition of USP14. We believe that by inhibition of USP14, vem resistance can be reversed and will finally benefit melanoma patients in future.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 2","pages":"316-328"},"PeriodicalIF":4.3,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138174997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma","authors":"Luka de Vos-Hillebrand,&nbsp;Simon Fietz,&nbsp;Philip Hillebrand,&nbsp;Zsófi Kulcsár,&nbsp;Marie Yatou Diop,&nbsp;Sarah Hollick,&nbsp;Alexander Philippe Maas,&nbsp;Sebastian Strieth,&nbsp;Jennifer Landsberg,&nbsp;Dimo Dietrich","doi":"10.1111/pcmr.13151","DOIUrl":"10.1111/pcmr.13151","url":null,"abstract":"<p>The immune-modulating protein CD52 attenuates lymphocyte function and is associated with autoimmune disorders, for example, multiple sclerosis (MS). CD52 represents a therapeutic target in MS and chronic lymphocytic leukemia (CLL). Its expression has prognostic and predictive value in CLL and is prognostic in breast cancer. Its significance in melanoma is unclear. We analyzed <i>CD52</i> mRNA expression data from tumor bulk tissues of <i>N</i> = 445 untreated melanoma patients from The Cancer Genome Atlas (TCGA) Research Network and of <i>N</i> = 121 melanoma patients undergoing anti-PD-1 immune checkpoint blockade (ICB) with regard to outcome (overall survival [OS], disease control [DC], and progression-free survival [PFS]), single-cell RNA-Seq data of <i>N</i> = 4645 cells from <i>N</i> = 19 melanoma tissues, and <i>N</i> = 15,457 cells from normal skin provided by <i>N</i> = 5 donors. Higher <i>CD52</i> mRNA expression was associated with favorable OS (hazard ratio (HR) = 0.820, [95% CI 0.734–0.916], <i>p</i> &lt; .001) in non-ICB-treated melanoma and with PFS (HR = 0.875, [95% CI 0.775–0.989], <i>p</i> = .033) and DC (<i>p</i> = .005) in ICB-treated melanoma. <i>CD52</i> expression correlated significantly with distinct immune cell subsets and correlated negatively with immune checkpoint expression in T cells. Moreover, our results suggest <i>CD52</i> expression by a certain type of tissue-resident macrophages. <i>CD52</i> mRNA was expressed in a small subgroup (8%) of immune checkpoint coexpressing melanoma cells. <i>CD52</i> expression is associated with features of ICB response in melanoma. Concomitant ICB and anti-CD52 treatment requires critical review.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 2","pages":"309-315"},"PeriodicalIF":4.3,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.13151","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136395483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-cell profiling of MC1R-inhibited melanocytes","authors":"H. Matthew Berns,&nbsp;Dawn E. Watkins-Chow,&nbsp;Sizhu Lu,&nbsp;Pakavarin Louphrasitthiphol,&nbsp;Tongwu Zhang,&nbsp;Kevin M. Brown,&nbsp;Pedro Moura-Alves,&nbsp;Colin R. Goding,&nbsp;William J. Pavan","doi":"10.1111/pcmr.13141","DOIUrl":"10.1111/pcmr.13141","url":null,"abstract":"<p>The human red hair color (RHC) trait is caused by increased pheomelanin (red-yellow) and reduced eumelanin (black-brown) pigment in skin and hair due to diminished melanocortin 1 receptor (MC1R) function. In addition, individuals harboring the RHC trait are predisposed to melanoma development. While <i>MC1R</i> variants have been established as causative of RHC and are a well-defined risk factor for melanoma, it remains unclear mechanistically why decreased MC1R signaling alters pigmentation and increases melanoma susceptibility. Here, we use single-cell RNA sequencing (scRNA-seq) of melanocytes isolated from RHC mouse models to define a MC1R-inhibited Gene Signature (MiGS) comprising a large set of previously unidentified genes which may be implicated in melanogenesis and oncogenic transformation. We show that one of the candidate MiGS genes, TBX3, a well-known anti-senescence transcription factor implicated in melanoma progression, binds both E-box and T-box elements to regulate genes associated with melanogenesis and senescence bypass. Our results provide key insights into further mechanisms by which melanocytes with reduced MC1R signaling may regulate pigmentation and offer new candidates of study toward understanding how individuals with the RHC phenotype are predisposed to melanoma.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 2","pages":"291-308"},"PeriodicalIF":4.3,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.13141","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136395484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TFE3 promotes ferroptosis in melanoma","authors":"Diogo Dias,&nbsp;Pakavarin Louphrasitthiphol,&nbsp;Colin R. Goding","doi":"10.1111/pcmr.13149","DOIUrl":"10.1111/pcmr.13149","url":null,"abstract":"<p>\u0000 \u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 2","pages":"286-290"},"PeriodicalIF":4.3,"publicationDate":"2023-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.13149","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89716227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IPCC2023: Looking for translational opportunities by persevering in basic pigment cell research","authors":"María D. Boyano,&nbsp;Aintzane Asumendi,&nbsp;José Carlos Garcia-Borrón,&nbsp;Lluís Montoliu,&nbsp;Santos Alonso","doi":"10.1111/pcmr.13148","DOIUrl":"10.1111/pcmr.13148","url":null,"abstract":"","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 5","pages":"546-554"},"PeriodicalIF":3.9,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71419001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytoglobin functions as a redox regulator of melanogenesis in normal epidermal melanocytes","authors":"Yo Tanaka,&nbsp;Misako Sato-Matsubara,&nbsp;Daisuke Tsuruta,&nbsp;Hiroshi Tanaka,&nbsp;Chiho Kadono,&nbsp;Koji Sugawara,&nbsp;Norifumi Kawada,&nbsp;Kazumasa Wakamatsu,&nbsp;Shosuke Ito,&nbsp;Katsutoshi Yoshizato","doi":"10.1111/pcmr.13146","DOIUrl":"10.1111/pcmr.13146","url":null,"abstract":"<p>Epidermal melanocytes are continuously exposed to sunlight-induced reactive oxygen species (ROS) and oxidative stress generated during the synthesis of melanin. Therefore, they have developed mechanisms that maintain normal redox homeostasis. Cytoglobin (CYGB), a ubiquitously expressed intracellular iron hexacoordinated globin, exhibits antioxidant activity and regulates the redox state of mammalian cells through its activities as peroxidase and nitric oxide (NO) dioxygenase. We postulated that CYGB functions in the melanogenic process as a regulator that maintains oxidative stress within a physiological level. This was examined by characterizing normal human melanocytes with the knockdown (KD) of <i>CYGB</i> using morphological and molecular biological criteria. <i>CYGB</i>-KD cells were larger, had more dendrites, and generated more melanin granules in the advanced stages of melanogenesis than control cells. The expression levels of major melanogenesis-associated genes and proteins were higher in <i>CYGB</i>-KD melanocytes than in wild type (WT) cells. As expected, <i>CYGB</i>-KD melanocytes generated more ROS and NO than WT cells. In conclusion, CYGB physiologically contributes to maintaining redox homeostasis in the melanogenic activity of normal melanocytes by controlling the intracellular levels of ROS and NO.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 2","pages":"276-285"},"PeriodicalIF":4.3,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71419000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"20th Anniversary of the Society for Melanoma Research: Celebrating two decades of progress in melanoma research","authors":"Ravi Amaravadi,&nbsp;Andrew Aplin,&nbsp;Meenhard Herlyn,&nbsp;Sheri Holmen,&nbsp;Richard White,&nbsp;Jessie Villanueva","doi":"10.1111/pcmr.13134","DOIUrl":"10.1111/pcmr.13134","url":null,"abstract":"&lt;p&gt;Dear Colleagues,&lt;/p&gt;&lt;p&gt;It is with great enthusiasm that we look forward to welcoming you to Philadelphia to celebrate a milestone for the melanoma research community: the &lt;i&gt;20th Anniversary of the Society for Melanoma Research (SMR)&lt;/i&gt;. The SMR was established in 2003 during the First International Melanoma Research Congress in Philadelphia. Meenhard Herlyn and Kate O'Neill were the driving force behind the inaugural SMR congress. Kate O'Neill wanted to honor the memory of her sister Noreen, who sadly lost her battle with melanoma. Four years earlier, Kate, Noreen, and Meenhard came together to establish the Noreen O'Neill Foundation for Melanoma Research, which served as the sponsor for the first SMR congress. They jointly envisioned a global community of basic scientists and clinicians sharing their expertise to combat one of the most challenging and deadly forms of cancer. Over the years this vision has become a reality, and a united community with almost 700 members has emerged. The SMR Congress brings together clinicians and scientists from diverse backgrounds to openly share their insights and latest research, and foster collective efforts aimed at battling melanoma.&lt;/p&gt;&lt;p&gt;The SMR has fostered numerous productive collaborations and nurtured the growth of rising talents. By promoting mentorship, exchange of knowledge and resources, and open discussions within the society's annual meetings, the SMR has supported the career of both junior and established researchers, as well as inspired the next generation of melanoma scientists.&lt;/p&gt;&lt;p&gt;In the past 20 years, groundbreaking discoveries and novel therapeutic approaches have shaped the landscape of melanoma treatment. From decoding the complexities of melanoma genetics, unraveling the intricate interactions within the tumor microenvironment, to developing immunotherapies that have revolutionized the treatment of melanoma, the collective efforts of the SMR community have brought us closer to conquering this challenging disease.&lt;/p&gt;&lt;p&gt;To mark the SMR's 20th Anniversary, some of our colleagues reflect on the past two decades, revisiting pivotal moments, landmark discoveries, and the evolution of our society. In this special issue of &lt;i&gt;PCMR&lt;/i&gt;, the contributing authors will take us through a journey, tracing the progress of the field under the SMR umbrella.&lt;/p&gt;&lt;p&gt;We sincerely thank our colleagues who have contributed to this special issue, and those who have been part of this journey—researchers, clinicians, trainees, patients, and advocates. The progress made is tangible proof of the power of collaboration, which has placed the melanoma field at the forefront of cancer research uncovering a therapeutic armamentarium that has revolutionized the clinical management of melanoma.&lt;/p&gt;&lt;p&gt;We invite you to join us in Philadelphia to celebrate the accomplishments of the field and the many melanoma researchers who have dedicated their careers to investigating and combating this challenging disease. Here","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"36 6","pages":"562"},"PeriodicalIF":4.3,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71409995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}